Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Achieving effective and safe anti-cancer small molecules is challenging due to lack of selectivity.
• The myeloid cell leukemia-1 (Mcl-1) and p53 upregulated modulator of apoptosis (PUMA) protein interface is a validated target for cancer therapy.
• Disrupting Mcl-1-PUMA binding can decrease cancer cell survival and protect normal cells.

Purpose of the Study:

• To identify small molecules targeting the Mcl-1-PUMA protein interface.
• To develop novel anti-cancer agents with improved selectivity and safety.

Main Methods:

• Pharmacophore modelling was employed to identify potential small-molecule inhibitors.
• Biological tests were conducted to validate the activity of identified compounds.

Main Results:

• A novel small-molecule compound targeting the Mcl-1-PUMA interface was identified for the first time.
• The compound demonstrated dual activity: reducing PUMA-dependent apoptosis and deactivating Mcl-1-mediated anti-apoptosis in cancer cells.

Conclusions:

• The identified small molecule offers a new therapeutic strategy for cancer treatment.
• This approach holds potential for developing effective and safe anti-cancer agents by targeting the Mcl-1-PUMA interaction.